PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
This Quarter Return
+0.2%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$645M
AUM Growth
+$645M
(-16%)
Cap. Flow
-$61.9M
Cap. Flow
% of AUM
-9.6%
Top 10 Holdings %
Top 10 Hldgs %
76.62%
Holding
47
New
2
Increased
6
Reduced
10
Closed
4
Top Buys
| 1 |
NovoCure
NVCR
|
$6.58M |
| 2 |
PTC Therapeutics
PTCT
|
$5.5M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
$4.12M |
| 4 |
BCYC
Bicycle Therapeutics
BCYC
|
$2.65M |
| 5 |
Pyxis Oncology
PYXS
|
$1.35M |
Top Sells
| 1 |
Insmed
INSM
|
$23.3M |
| 2 |
STAAR Surgical
STAA
|
$14.4M |
| 3 |
United Therapeutics
UTHR
|
$9.71M |
| 4 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$8.37M |
| 5 |
SAGE
Sage Therapeutics
SAGE
|
$7.3M |
Sector Composition
| 1 | Healthcare | 97.26% |
| 2 | Financials | 2.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $111M | 17.15% | 1,603,465 -337,528 | -17% | -$23.3M |
|
2
Amicus Therapeutics
FOLD
$2.34B
| $72.2M | 11.18% | 7,662,479 -482,832 | -6% | -$4.55M |
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $70.2M | 10.87% | 1,067,266 -22,790 | -2% | -$1.5M |
|
|
4
United Therapeutics
UTHR
$13.8B
| $54.9M | 8.51% | 155,714 -27,532 | -15% | -$9.71M |
|
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $50.4M | 7.82% | 2,748,599 +224,643 | +9% | +$4.12M |
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $33.1M | 5.13% | 140,681 | – | – |
|
7
Biogen
BIIB
$19.4B
| $29.1M | 4.51% | 190,148 -38,768 | -17% | -$5.93M |
|
8
Sarepta Therapeutics
SRPT
$1.78B
| $25.6M | 3.96% | 210,258 | – | – |
|
|
9
NovoCure
NVCR
$1.38B
| $24.3M | 3.76% | 814,191 +220,651 | +37% | +$6.58M |
|
10
Prothena Corp
PRTA
$441M
| $24.1M | 3.73% | 1,737,964 | – | – |
|
11
Iovance Biotherapeutics
IOVA
$807M
| $22.5M | 3.49% | 3,041,685 | – | – |
|
12
eHealth
EHTH
$118M
| $17.7M | 2.74% | 1,878,127 -469,392 | -20% | -$4.41M |
|
|
13
PTC Therapeutics
PTCT
$3.92B
| $17.4M | 2.7% | 386,413 +121,944 | +46% | +$5.5M |
|
|
14
STAAR Surgical
STAA
$1.36B
| $12.2M | 1.88% | 500,775 -590,833 | -54% | -$14.4M |
|
15
AnaptysBio
ANAB
$569M
| $11.2M | 1.73% | 843,971 | – | – |
|
16
Alkermes
ALKS
$4.78B
| $8.32M | 1.29% | 289,308 -95,348 | -25% | -$2.74M |
|
17
Align Technology
ALGN
$10.3B
| $7.88M | 1.22% | 37,772 | – | – |
|
18
Gossamer Bio
GOSS
$562M
| $5.68M | 0.88% | 6,277,093 | – | – |
|
|
SLRN
19
DELISTED
ACELYRIN
SLRN
| $5.63M | 0.87% | 1,792,895 | – | – |
|
20
Syndax Pharmaceuticals
SNDX
$1.41B
| $5.36M | 0.83% | 405,193 | – | – |
|
|
BCYC
21
Bicycle Therapeutics
BCYC
$511M
| $3.49M | 0.54% | 248,934 +189,352 | +318% | +$2.65M |
|
22
Karyopharm Therapeutics
KPTI
$61.7M
| $3.32M | 0.51% | 4,907,001 -195,192 | -4% | -$132K |
|
|
VERV
23
DELISTED
Verve Therapeutics
VERV
| $3.25M | 0.5% | 575,817 | – | – |
|
24
Edwards Lifesciences
EW
$47.8B
| $2.92M | 0.45% | 39,473 | – | – |
|
25
BioNTech
BNTX
$24B
| $2.87M | 0.45% | 25,206 | – | – |
|